Literature DB >> 2283512

Comparison of motor response to apomorphine and levodopa in Parkinson's disease.

P A Kempster1, J P Frankel, G M Stern, A J Lees.   

Abstract

The magnitude and pattern of motor responses to single doses of subcutaneous apomorphine and oral levodopa were compared in 14 patients with Parkinson's disease. Although apomorphine produced much shorter motor responses than levodopa, the quality of response to the two drugs was virtually indistinguishable. These clinical observations support the notion that integrity of striatal post-synaptic dopamine receptors is a key determinant of responsiveness to dopaminergic treatment in Parkinson's disease.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2283512      PMCID： PMC488286          DOI： 10.1136/jnnp.53.11.1004

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


  11 in total

1.  Subcutaneous apomorphine in Parkinson's disease.

Authors:  P Pollak; A S Champay; M Hommel; J E Perret; A L Benabid
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-04       Impact factor: 10.154

2.  Does an inhibitory action of levodopa contribute to motor fluctuations?

Authors:  J G Nutt; S T Gancher; W R Woodward
Journal:  Neurology       Date:  1988-10       Impact factor: 9.910

3.  Injected apomorphine and orally administered levodopa in Parkinsonism.

Authors:  S E Düby; G C Cotzias; P S Papavasiliou; W H Lawrence
Journal:  Arch Neurol       Date:  1972-12

4.  Comparison of effects of L-dopa, amphetamine and apomorphine on firing rate of rat dopaminergic neurones.

Authors:  B S Bunney; G K Aghajanian; R H Roth
Journal:  Nat New Biol       Date:  1973-09-26

5.  Apomorphine in Parkinsonian tremor.

Authors:  J Braham; I Sarova-Pinhas; Y Goldhammer
Journal:  Br Med J       Date:  1970-09-26

6.  Subcutaneous apomorphine for on-off oscillations in Parkinson's disease.

Authors:  K R Chaudhuri; P Critchley; R J Abbott; I F Pye; P A Millac
Journal:  Lancet       Date:  1988-11-26       Impact factor: 79.321

7.  Subcutaneous apomorphine in parkinsonian on-off oscillations.

Authors:  C M Stibe; A J Lees; P A Kempster; G M Stern
Journal:  Lancet       Date:  1988-02-20       Impact factor: 79.321

8.  Subcutaneous apomorphine in Parkinson's disease.

Authors:  W Poewe; B Kleedorfer; F Gerstenbrand; W Oertel
Journal:  Lancet       Date:  1988-04-23       Impact factor: 79.321

9.  Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease.

Authors:  P A Kempster; J P Frankel; M Bovingdon; R Webster; A J Lees; G M Stern
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154

10.  Dopamine"autoreceptors": pharmacological characterization by microiontophoretic single cell recording studies.

Authors:  G K Aghajanian; B S Bunney
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-03       Impact factor: 3.000
View more
  15 in total

1.  Cardiovascular reflexes in Parkinson's disease: effect of domperidone and apomorphine.

Authors:  M Merello; Z Pirtosek; S Bishop; A J Lees
Journal:  Clin Auton Res       Date:  1992-08       Impact factor: 4.435

2.  The clinical use of apomorphine in Parkinson's disease.

Authors:  M J Steiger; N P Quinn; C D Marsden
Journal:  J Neurol       Date:  1992-08       Impact factor: 4.849

3.  Comparative Review of Dopamine Receptor Agonists in Parkinson's Disease.

Authors:  R J Uitti; J E Ahlskog
Journal:  CNS Drugs       Date:  1996-05       Impact factor: 5.749

4.  The dopamine receptor agonist apomorphine stabilizes neurotoxic α-synuclein oligomers.

Authors:  Vanderlei de Araujo Lima; Rodrigo Esquinelato; Phelippe Carmo-Gonçalves; Lucas Alex do Nascimento; Hudson Lee; David Eliezer; Luciana Romão; Cristian Follmer
Journal:  FEBS Lett       Date:  2021-12-29       Impact factor: 4.124

Review 5.  Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.

Authors:  Dirk Deleu; Yolande Hanssens; Margaret G Northway
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

6.  Imaging apomorphine stimulation of brain arachidonic acid signaling via D2-like receptors in unanesthetized rats.

Authors:  Abesh Kumar Bhattacharjee; Lisa Chang; Laura White; Richard P Bazinet; Stanley I Rapoport
Journal:  Psychopharmacology (Berl)       Date:  2008-02-15       Impact factor: 4.530

7.  Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up.

Authors:  K Pietz; P Hagell; P Odin
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-11       Impact factor: 10.154

8.  Usefulness of movement time in the assessment of Parkinson's disease.

Authors:  M Zappia; R Montesanti; R Colao; A Quattrone
Journal:  J Neurol       Date:  1994-08       Impact factor: 4.849

Review 9.  Pharmacological Insights into the Use of Apomorphine in Parkinson's Disease: Clinical Relevance.

Authors:  Manon Auffret; Sophie Drapier; Marc Vérin
Journal:  Clin Drug Investig       Date:  2018-04       Impact factor: 2.859

Review 10.  Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations.

Authors:  Federico Carbone; Atbin Djamshidian; Klaus Seppi; Werner Poewe
Journal:  CNS Drugs       Date:  2019-09       Impact factor: 5.749
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.